Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:53:32 07/06/2024 pm IST			5-day change	1st Jan Change
10.1 ^SEK	-0.98%		-1.46%	+9.31%

10/05	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/02	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024

May 10, 2024 at 12:00 pm IST

Initiator Pharma A/S reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was DKK 4.12 million compared to DKK 9.27 million a year ago. Basic loss per share from continuing operations was DKK 0.08 compared to DKK 0.18 a year ago.

Latest news about Initiator Pharma A/S

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02	CI
Initiator Pharma Issues New Shares for Debt Conversion	21/02	MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	08/01	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	06/23/06	CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	19/23/19	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25	CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate	09/23/09	MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	09/23/09	CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	18/23/18	CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	05/23/05	CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	29/23/29	CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	05/23/05	CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired.	26/23/26	CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	02/23/02	CI
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02	CI
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	06/23/06	CI
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	20/22/20	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	04/22/04	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/22/04	CI
Initiator Pharma A/S Provides an Update on Its Clinical Programs	04/22/04	CI
Certain Ordinary Shares of Initiator Pharma A/S are subject to a Lock-Up Agreement Ending on 3-OCT-2022.	03/22/03	CI
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	21/22/21	CI

Chart Initiator Pharma A/S

Duration

Period

More charts

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Sector

Biotechnology & Medical Research

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INITIATOR PHARMA A/S	+9.31%	51.87M
MODERNA, INC.	+53.71%	59.28B
LONZA GROUP AG	+41.42%	40.94B
IQVIA HOLDINGS INC.	-5.57%	40.17B
CELLTRION, INC.	-5.56%	28.69B
ICON PUBLIC LIMITED COMPANY	+12.39%	26.63B
ALNYLAM PHARMACEUTICALS, INC.	-20.82%	18.89B
MEDPACE HOLDINGS, INC.	+30.01%	12.46B
BIO-TECHNE CORPORATION	+0.60%	12.42B
UNITED THERAPEUTICS CORPORATION	+26.60%	12.26B

Other Biotechnology & Medical Research